Advertisement
The American Journal of Cardiology®
Advanced SearchSave search
Symposium on catecholamines in cardiovascular pathology| Volume 5, ISSUE 5, P613-618, May 01, 1960

Circulating epinephrine and norepinephrine in coronary occlusion∗

DOI:https://doi.org/10.1016/0002-9149(60)90126-0
Circulating epinephrine and norepinephrine in coronary occlusion∗
Previous ArticleThe adrenosympathetic and adrenocortical function in cardiac insufficiency∗
Next ArticlePathologic changes induced by 1-norepinephrine
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      • 1.
        1. Following experimental coronary occlusion in thirty-nine dogs, mean values of norepinephrine increased maximally from 1.6 to 10.5 μg-/L. of plasma in thirty-three surviving animals. Serum transaminase increments paralleled norepinephrine elevations in most instances. No changes occurred in circulating levels of epinephrine. Recordings of fluorescence emission spectrums aided in the identification and quantitation of the catecholamines.
      • 2.
        2. Essentially the same results occurred in four chronically adrenalectomized dogs.
      • 3.
        3. Following coronary occlusion and the administration of a sympatholytic agent (tri-methyl-2-2,6 xylyloxy-propyl ammonium chloride monohydrate), elevated circulating levels of norepinephrine declined progressively to pre-occlusion figures.
      • 4.
        4. Of eighteen dogs treated with reserpine, eleven survived the occlusive procedure and showed increments in norepinephrine and transaminase similar to those of the untreated animals,
      • 5.
        5. The catecholamine content of the infarct and the adjacent area was not elevated above the values found in normal tissue.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Raab W.
        Abnormal suprarenal discharges in angina pectoris and their control by x-ray therapy.
        J. Clin. Endocrinol. 1941; 1: 977
        • Nuzum F.R.
        • Bischoff F.
        The urinary output of catechol derivatives including adrenaline in normal individuals, in essential hypertension and in myocardial infarction.
        Circulation. 1953; 7: 96
        • Raab W.
        • Gigee W.
        Total urinary catechol excretion in cardiovascular and other clinical conditions.
        Circulation. 1954; 9: 592
        • Raab W.
        • Gigee W.
        Norepinephrine and epinephrine content of normal and diseased human hearts.
        Circulation. 1955; 11: 593
        • Bloodworth Jr., J.M.B.
        • von Haam E.
        The tissue catecholamine concentration of the human heart determined by the aluminum hydroxide-arsenomolybdic acid method.
        Circulation. 1956; 13: 573
        • Gazes P.C.
        • Richardson J.A.
        • Woods E.F.
        Plasma catecholamine concentrations in myocardial infarction and angina pectoris.
        Circulation. 1959; 19: 657
        • Starcich R.
        • Ambanelli U.
        Importanza della determinazione delle catecolamine plasmatiche in patologia coronarica.
        Gior. clin. med. 1959; 40 (fasc. 2)
        • Richardson J.A.
        • Richardson A.K.
        • Brodie O.J.
        Fluorimetric determination of epinephrine and norepinephrine in plasma.
        J. Lab. & Clin. Med. 1956; 47: 832
        • Manger W.M.
        • Wakim K.G.
        • Bollman J.L.
        Chemical Quantitation of Epinephrine and Norepinephrine in Plasma.
        Charles C Thomas, Springfield, Illinois1959
        • Boniface K.J.
        • Brodie O.J.
        • Walton R.P.
        Resistance strain gauge arches for direct measurement of heart contractile force in animals.
        in: 11th ed. Proc. Soc. Exper. Biol. & Med.84. 1953: 263
        • Cotten M.deV.
        • Maling H.M.
        Relationships among stroke work, contractile force and fiber length during changes in ventricular function.
        Am. J. Physiol. 1957; 189: 580
        • Harris A.S.
        • Bisteni A.
        Effects of sympathetic blockade drugs on ventricular tachycardia resulting from myocardial infarction.
        Am. J. Physiol. 1955; 181: 559
        • Richardson J.A.
        • Woods E.F.
        • Gazes P.C.
        • Bagwell E.E.
        Plasma catecholamines in coronary occlusion and angina pectoris.
        in: 11th ed. Fed. Proc.18. 1959: 437
        • Goldberg L.I.
        • Cotten M.deV.
        • Darby T.D.
        • Howell E.F.
        Comparative heart contractile force effects of equipressor doses of several sympathomimetic amines.
        J. Pharmacol. & Exper. Therap. 1953; 108: 177
        • Bloodwell R.D.
        • Goldberg L.I.
        • Braunwald E.
        • Morrow A.G.
        Direct studies of myocardial contractility in man.
        Circulation. 1959; 20: 673
        • Gazes P.C.
        • Goldberg L.I.
        • Darby T.D.
        Heart force effects of sympathomimetic amines as a basis for their use in shock accompanying myocardial infarction.
        Circulation. 1953; 8: 883
        • Raab W.
        The adrenergic-cholinergic control of cardiac metabolism and function.
        Advances Cardiol. 1956; 1: 65
        • Fleischer M.S.
        • Loeb L.
        Experimental myocarditis.
        Arch. Int. Med. 1909; 3: 78
        • Christian H.A.
        • Smith R.M.
        • Walker I.C.
        Experimental cardiorenal disease.
        Arch. Int. Med. 1911; 8: 468
        • Szakacs J.E.
        • Cannon A.
        1-Norepinephrine myocarditis.
        Am. J. Clin. Path. 1958; 30: 425
        • Raab W.
        The pathogenic significance of adrenalin and related substances in heart muscle.
        Exper. Med. & Surg. 1943; 1: 188
        • Exley K.A.
        The blocking action of choline 2:6-xylyl ether bromide on adrenergic nerves.
        Brit. J. Pharmacol. 1957; 12: 297

      23. Woods, E. F., Richardson, J. A. and Bagwell, E. E. Influence of reserpine on adrenal medullary responses to direct chemical stimulation. Proc. Soc. Exper. Biol. & Med., in press.

        • Kroneberg G.
        • Schümann H.J.
        Adrenalin-sekretion und Adrenalinverarmung der Kanin-chennebennieren nach Reserpin.
        Arch. exper. Path. u. Pharmakol. 1958; 234: 133
        • Maling H.M.
        • Cohn V.H.
        • Highman B.
        The effects of coronary occlusion in dogs treated with reserpine and in dogs treated with phenoxybenzamine.
        J. Pharmacol. & Exper. Therap. 1959; 127: 229
        • von Euler U.S.
        Noradrenaline.
        Charles C Thomas, Springfield, Illinois1956
        • Richardson J.A.
        • Woods E.F.
        Release of norepinephrine from the isolated heart.
        in: 11th ed. Proc. Soc. Exper. Biol. & Med.100. 1959: 149
        • Raab W.
        • Gigee W.
        Specific avidity of the heart muscle to absorb and store epinephrine and norepinephrine.
        Circulation Res. 1955; 3: 553
        • Hercules D.M.
        Some factors affecting fluorescence maxima.
        Science. 1957; 125: 1242

      Article Info

      Publication History

      with the technical assistance of Douglas C. Owens and Marcy S. Walsh

      Footnotes

      ☆This work was supported by grants from the American Heart Association and National Heart Institute, U. S. Public Health Service (H-1846 C-4 and HTS-5200).

      Identification

      DOI: https://doi.org/10.1016/0002-9149(60)90126-0

      Copyright

      © 1960 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2022 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX